NOVARTIS

Black Friday sale offers 20% off The Scenarionist Premium Annual Plan. Deep Tech Briefing #40 covers AI policy, startup funding, eVTOL sector challenges, AI standards, space tech advancements, protein AI innovation, energy scaling issues, and quantum computing progress.

DelveInsight's 'Graft versus host disease Pipeline Insight 2024' covers 60+ companies and 65+ pipeline drugs, including clinical and nonclinical stage products, with a focus on therapeutics assessment by product type, stage, route of administration, and molecule type. Key companies and promising therapies in development are highlighted.

India's biopharma sector grew to $53.8 billion in 2023, driven by biotechnology advances, personalised medicine, and biosimilars. India is a major vaccine supplier, with SII accounting for 24% of the global market. Innovations include indigenous mRNA vaccines and Hepatitis A vaccine. India launched its first affordable CAR-T therapy, NexCAR19, in 2024. Precision health initiatives like Phenome India and AI-Precision Oncology Centre were launched. Strategic partnerships and the BioE3 Policy aim to strengthen biomanufacturing. Regulatory challenges and quality concerns persist, but future prospects include advanced therapies and potential benefits from the U.S. Biosecure Act.

Pluvicto, a new prostate cancer treatment using lutetium-177, costs $27,000 per dose, totaling $135,000 for an average five-dose treatment. The pan-Canadian Pharmaceutical Alliance (pCPA) ended negotiations with Novartis, leaving patients to fund the treatment themselves. Health Canada approved Pluvicto in 2022, but coverage is unavailable in B.C. without third-party insurance or private payment. Patients and advocates call for renewed negotiations to make the treatment accessible.

Roche to acquire Poseida Therapeutics for $1 billion. Merck, AstraZeneca, and Novartis see success in new drug studies. Novartis' Kisqali approved for broader breast cancer treatment in EU.

Clascoterone, a new acne treatment, is available in the US but not yet in Europe. It targets hormonal causes of acne without significant side effects, but its effectiveness compared to existing treatments is unclear. Cosmo Pharmaceuticals, the producer, is seeking distribution partners globally, citing the pandemic as a delay factor.

Niven R. Narain emphasizes that AI investments in drug development require robust data and validation. GEN's A-List highlights 10 AI-based drug discovery leaders, including BPGbio, which focuses on cancer energy generation. Other notable companies include Nvidia and Palantir Technologies, though not on the A-List. The list includes specifics on companies like Anima Biotech, Atomwise, and Nimbus Therapeutics, detailing their AI platforms and drug development progress.

DelveInsight's report on the Gene and Cell Therapies Targeting CNS Disorders market forecasts growth to 2034, highlighting key companies and therapies, including Bayer AG's Phase Ib clinical trial success for Parkinson's disease and uniQure's positive trends in Huntington's disease trials. The market, valued at approximately USD 1 billion in 2021, is expected to surge due to increasing disease prevalence and pipeline product launches.

The antibiotics and antimycotics market is projected to reach $91.54 billion by 2031, driven by infectious disease prevalence and R&D initiatives. Key players include Pfizer, Novartis, and Sanofi. North America leads in revenue, with APAC expected to show highest growth.